Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

57.1%

4 terminated/withdrawn out of 7 trials

Success Rate

42.9%

-43.6% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

3(42.9%)

Phase 1

2(28.6%)

Early Phase 1

1(14.3%)

Phase 4

1(14.3%)

7Total

N/A(3)

Phase 1(2)

Early Phase 1(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT05708313Not ApplicableCompleted

Effects of 9-18 Weeks of Intensive Cardiac Rehabilitation After a Major Cardiovascular Event in Patients With CVD

Role: lead

NCT02161744Phase 1Terminated

Safety, Tolerability and Preliminary Efficacy of Adipose Derive Stem Cells for Patients With COPD

Role: lead

NCT03455374Not ApplicableTerminated

Diamondback in Peripheral Vascular Disease

Role: lead

NCT02756884Early Phase 1Completed

Safety and Preliminary Efficacy of Adipose Derived Stem Cells and Low Frequency Ultrasound in PAD

Role: lead

NCT02734836Not ApplicableCompleted

Drug Eluting Stent for the Management of PERipheral Arterial Disease Of the SFA (DESPERADO-SFA Study)

Role: lead

NCT02407314Phase 4Terminated

Ticagrelor and Peripheral Arterial Disease

Role: lead

NCT02741362Phase 1Terminated

Safety and Efficacy of Adipose Derived Stem Cells in Refractory Rheumatoid Arthritis, Systemic Lupus Erythematosus or Sharp's Syndrome

Role: lead

All 7 trials loaded